Dr. von Hehn is a clinical development scientist joining RSRT from Concert Pharmaceuticals. She has over 10 years of experience in drug development and has worked in a variety of neurodevelopmental and central nervous system disorders, including autism and fragile X syndrome, pediatric and adult seizure disorders, and life-threatening status epilepticus. She also has experience in oncology, dermatology, and respiratory indications.
During her tenure in drug development she has been responsible for clinical development planning, protocol development, novel endpoint design, clinical trial execution, data analysis and reporting, and has managed several clinical operations teams to successfully move clinical programs forward. She has experience developing programs without a regulatory precedent. In 2017, Dr. von Hehn was invited to be a visiting professor at Framingham State University to teach a master’s level course on scientific concepts and clinical trial development.
Prior to industry, Dr. van Hehn earned her PhD in genetics and molecular biology from Emory University under the direction of Dr. Gerald Shadel. Half-way through her graduate work, the Shadel lab moved to Yale University and Dr. van Hehn completed three years of her studies as a visiting PhD student at Yale. Her academic career at Emory and Yale focused on the single-gene pediatric disorders galactosemia and ataxia-telangiectasia, where she authored and contributed to numerous peer-reviewed publications. Prior to Emory she earned a bachelor of science in molecular and microbiology from the University of Central Florida. Dr. van Heh is a native Floridian who currently resides in Boston, Mass., with her husband and their two children.